Please assess the completion status of the following clinical trial:

Trial Title: Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~1. Diagnosis of intermittent asthma according to Global Initiative for Asthma criteria~2. Non-smokers or ex-smokers who have not smoked for at least 1 year and have a smoking history of less than 5 pack-years~3. Forced Expiratory Volume in 1second greater than or equal to 80% predicted normal (Visit 1).~4. Bronchial hyperresponsiveness to inhaled methacholine with a provocative concentration of a methacholine causing a 20% fall in Forced Expiratory Volume in one second less than or equal to 8 mg/mL (Visit 1).~5. Be able to perform technically acceptable pulmonary function tests~6. Be able to inhale medication in a competent manner from the Respimat® inhaler~7. Must sign and date an informed consent consistent with International Conference on Harmonisation-Good Clinical Practice guidelines prior to participation in the trial, which includes medication washout and restrictions.~Exclusion criteria~1. Patients with a significant disease other than asthma~2. Patients with seasonal asthma or allergies whose participation in the trial will occur during the season for which they are allergic.~3. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with a serum glutamic oxaloacetic transaminase \> 80 IU/L, serum glutamic pyruvic transaminase \> 80 IU/L, bilirubin \>2.0 mg/dL or creatinine \> 2.0 mg/dL will be excluded regardless of clinical condition~4. Patients with any of the following conditions: a diagnosis of hyperthyrosis or paroxysmal tachycardia (\>100 beats per minute), a marked baseline prolongation of QT/QTc interval, a history of additional risk factors for Torsade de Pointes, a history of myocardial infarction, a diagnosis of clinically relevant cardiac arrhythmia, a history of cor pulmonale, known active tuberculosis, a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years (patients with treated basal cell carcinoma are allowed), a history of life-threatening pulmonary obstruction, a history of cystic fibrosis, clinically evident bronchiectasis, or a history of significant alcohol or drug abuse.~5. Patients who have undergone thoracotomy with pulmonary resection~6. Patients who are being treated with any of the following concomitant medications: medications that prolong the QT/QTc interval, oral beta-adrenergics, beta-blockers or monoamine oxidase inhibitors or tricyclic antidepressants.~7. Patients who have been treated with any respiratory medications (excluding short-acting beta-agonists) for control of their asthma symptoms within 3 months of the Screening Visit (Visit 1).~8. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1).~9. Pregnant or nursing women, or women of childbearing potential not using a highly effective method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI1744) Low (Type: EXPERIMENTAL): Single dosing of low dose Olodaterol inhaled orally from Respimat Device
- Olodaterol (BI1744) Medium Low (Type: EXPERIMENTAL): Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
- Olodaterol (BI1744) Medium High (Type: EXPERIMENTAL): Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): Single dosing of high dose Olodaterol inhaled orally from Respimat Device
- Placebo (Type: PLACEBO_COMPARATOR): Single dosing of Olodaterol placebo inhaled orally from Respimat Device

Based on this trial design, predict the completion outcome and termination type (if applicable).